Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 9/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 9/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24673386 | 0.96 | NPC1 (0.39) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL24764415 | 0.88 | NPC1 (0.35) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL23568258 | 0.84 | NPC1 (0.37) | NPC1CARM1PRMT6HRH3 | |
| SCHEMBL22848886 | 0.84 | HRH3 (0.38) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL24672510 | 0.84 | NPC1 (0.34) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL24764431 | 0.84 | NPC1 (0.34) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL25468753 | 0.83 | CARM1 (0.48) | CARM1PRMT6HRH3TMEM97SIGMAR1 | |
| SCHEMBL25829052 | 0.82 | NPC1 (0.36) | NPC1CARM1PRMT6HRH3TMEM97 | |
| SCHEMBL23696478 | 0.81 | HTR2C (0.35) | CARM1PRMT6HRH3SIGMAR1 | |
| SCHEMBL24673656 | 0.81 | HRH3 (0.33) | NPC1CARM1PRMT6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | NPC1 2315/4885CARM1 1154/4885PRMT6 236/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885CARM1 824/4885PRMT6 1616/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885CARM1 824/4885PRMT6 1616/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885CARM1 824/4885PRMT6 1616/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885CARM1 824/4885PRMT6 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.